Deutsche Zeitschrift für Onkologie 2018; 50(03): 120-123
DOI: 10.1055/a-0652-4707
Forschung
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Immuntherapien mit Checkpoint-Inhibitoren – Eine Übersicht

Immunotherapies with Checkpoint Inhibitors – an Overview
Peter Holzhauer
1   Onkologisches Kompetenzzentrum Oberaudorf – Klinik Bad Trissl
2   Privatärztliche Praxisgemeinschaft, München
› Author Affiliations
Further Information

Publication History

Publication Date:
24 September 2018 (online)

Zusammenfassung

Das Konzept, Zellen des Immunsystems so zu aktivieren, dass eine ausreichend effektive Immunantwort gegen Tumorzellen erzielt werden kann, ist nicht neu. Bis zur klinischen Einführung der Checkpoint-Inhibitoren konnte sich aber keine Form der Immuntherapie, seien es Zytokin-basierte Therapien oder Therapiekonzepte mit aktivierten Effektorzellen, als ausreichend effektiv durchsetzen. In dieser Übersicht werden die wichtigsten heute zugelassenen Checkpoint-Inhibitoren bei verschiedenen Tumorentitäten vorgestellt.

Abstract

In addition to fighting and repelling pathogens such as bacteria, viruses and fungi, which can cause infections, the human immune system also has the task to eliminate altered, damaged and obsolete cells. The immunological processes are very complex and affect a whole network of effector cells, various messenger substances, so-called cytokines are activated or slowed down. So far, only a very few immunological treatment concepts were able to prevail in cancer therapy. Today, synthetically produced antibodies can recognize specifically altered or overexpressed protein structures such as receptors on the cell surface. They dock to such structures and then intervene in targeted processes of metabolism and growth of cancer cells.

So, the concept of activating cells of the immune system to achieve a sufficiently effective immune response against tumor cells is not new. However, until the clinical introduction of the checkpoint inhibitors, no form of immunotherapy, whether it was cytokine-based therapies or therapy concepts with activated effector cells, could prove sufficient effectiveness. This review presents the most important checkpoint inhibitors currently approved for various tumor entities.

 
  • Literatur

  • 1 Ansell SM, Lesokhin AM, Borrello I, Halwani A. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319 10.1056/NEJMoa1411087
  • 2 Calandri M, Solitro F, Angelino V. et al. The role of radiology in the evaluation of the immunotherapy efficacy. J Thorac Dis 2018; 10 (Suppl. 13) S1438-S1446 10.21037/jtd.2018.05.130
  • 3 Carlson BA, Yoo MH, Shrimali RK. et al. Role of selenium-containing proteins in T-cell and macrophage function. Proc Nutr Soc 2010; 69: 300-310 10.1017/S002966511000176X
  • 4 Fehrenbacher L, Spira A, Ballinger M. et al. POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-1846 10.1016/S0140-6736(16)00587-0
  • 5 Herbst RS, Baas P, Kim DW. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550 10.1016/S0140-6736(15)01281-7
  • 6 https://de.wikipedia.org/wiki/PD-L1
  • 7 https://www.esmo.org/content/download/133758/2490221/file/DE-ESMO-Patientenleitlinie-Immuntherapie-bedingte-Nebenwirkungen-und-ihr-Management.pdf
  • 8 IMpower150: Increased OS With Atezolizumab/Bevacizumab Plus Chemotherapy in Advanced Nonsquamous NSCLC, By The ASCO Post, Posted: 4/3/2018 2:22:46 PM, Last Updated: 4/3/2018 4:49:36 PM, Interimsanalyse, noch nicht publiziert
  • 9 Kaufman HL, Russell J, Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374-1385 .10.1016/S1470-2045(16)30364-3
  • 10 https://www.krebsinformationsdienst.de/fachkreise/nachrichten/2017/fk24-checkpointhemmer-atezolizumab.php
  • 11 Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Carboplatin and Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared to Avastin Plus Carboplatin and Paclitaxel. Genentech. Posted March 25, 2018. Accessed March 26, 2018. https://bit.ly/2IUPqG2.
  • 12 Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 76-83 10.14694/EdBook_AM.2015.35.76
  • 13 Reck M, Rodríguez-Abreu D, Robinson AG. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-1833 10.1056/NEJMoa1606774
  • 14 Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014; 33: 434-444 10.5732/cjc.014.10122
  • 15 Wolchok JD, Chiarion-Sileni V, Gonzalez R. et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 2017; 377: 1345-1356 10.1056/NEJMoa1709684